Kynos Therapeutics

Kynos Therapeutics is a biopharmaceutical, VC-backed spin-out from the University of Edinburgh developing inhibitors of kynurenine 3-monooxygenase (KMO). KMO produces harmful metabolites during inflammation, and its inhibition prevents tissue injury. Kynos’s pipeline is focused on three key areas: critical illness post

Kynos Therapeutics is a company in health.

Profile

Kynos Therapeutics is a biopharmaceutical, VC-backed spin-out from the University of Edinburgh developing inhibitors of kynurenine 3-monooxygenase (KMO). KMO produces harmful metabolites during inflammation, and its inhibition prevents tissue injury. Kynos’s pipeline is focused on three key areas: critical illness post-surgery, chronic inflammatory conditions, and cancer.

Within the health space, the company focuses on its core offering rather than a broad product line.

It is recorded at the Creative Destruction Lab alumni company stage.

Website: www.kynostx.com